{{Rsnum
|rsid=2048327
|Gene=SLC22A3
|Chromosome=6
|position=160442500
|Orientation=minus
|GMAF=0.3223
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=SLC22A3
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 38.9 | 51.3 | 9.7
| HCB | 27.7 | 51.1 | 21.2
| JPT | 28.3 | 45.1 | 26.5
| YRI | 99.3 | 0.7 | 0.0
| ASW | 80.7 | 17.5 | 1.8
| CHB | 27.7 | 51.1 | 21.2
| CHD | 33.9 | 45.9 | 20.2
| GIH | 46.5 | 47.5 | 5.9
| LWK | 91.8 | 8.2 | 0.0
| MEX | 39.7 | 44.8 | 15.5
| MKK | 80.1 | 19.9 | 0.0
| TSI | 51.0 | 36.3 | 12.7
| HapMapRevision=28
}}
{{PMID Auto GWAS
  |PMID=24262325
  |Trait=Coronary artery disease
  |Title=Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants.
  |RiskAllele=C
  |Pval=1E-6
  |OR=1.07
  |ORtxt=[1.05-1.10]
  }}
{{PMID Auto GWAS
  |PMID=19198611
  |Trait=Coronary artery disease
  |Title=Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease.
  |RiskAllele=
  |Pval=4E-15 (CCTC)
  |OR=1.82
  |ORtxt=[1.57-2.12]
  }}
{{PMID Auto GWAS
  |PMID=19198611
  |Trait=Coronary artery disease
  |Title=Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease.
  |RiskAllele=
  |Pval=1E-9 (CTTG)
  |OR=1.2
  |ORtxt=[1.13-1.28] 
  }}
{{PharmGKB
|RSID=rs2048327
|Name_s=
|Gene_s=SLC22A3
|Feature=
|Evidence=PubMed ID:19198611; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. (Initial Sample Size: 1,926 cases, 2,938 controls; Replication Sample Size: 7,073 cases, 7,325 controls); (Region: 6q25.3; Reported Gene(s): SLC22A3,LPAL2,LPA; Risk Allele: 4-SNP haplotype-1); (p-value= 0.000000001).This variant is associated with Coronary artery disease.
|Drugs=
|Drug Classes=
|Diseases=Cardiovascular Diseases
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164739976
}}
{{PharmGKB
|RSID=rs2048327
|Name_s=
|Gene_s=SLC22A3
|Feature=
|Evidence=PubMed ID:19198611; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. (Initial Sample Size: 1,926 cases, 2,938 controls; Replication Sample Size: 7,073 cases, 7,325 controls); (Region: 6q25.3; Reported Gene(s): SLC22A3,LPAL2,LPA; Risk Allele: 4-SNP haplotype-2); (p-value= 0.000000000000004).This variant is associated with Coronary artery disease.
|Drugs=
|Drug Classes=
|Diseases=Cardiovascular Diseases
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164739978
}}
{{PMID Auto
|PMID=20429798
|Title=Association of the SLC22A1, SLC22A2, and SLC22A3 genes encoding organic cation transporters with diabetic nephropathy and hypertension.
}}
{{PMID Auto
|PMID=19956433
|Title=Genetics of coronary artery disease: focus on genome-wide association studies.
|OA=1
}}
{{PMID Auto
|PMID=19591196
|Title=Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver
}}
{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2048327
|overall_frequency_n=36
|overall_frequency_d=128
|overall_frequency=0.28125
|n_genomes=22
|n_genomes_annotated=0
|n_haplomes=28
|n_articles=0
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}